.jpg)
.jpg)
.jpg)
Wednesday, December 28, 2016
Wednesday, December 21, 2016
Wednesday, December 14, 2016
Thursday, December 8, 2016
Wednesday, November 30, 2016
Thursday, November 24, 2016
Monday, November 21, 2016
Tuesday, November 8, 2016
Call For Paper
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of
Wednesday, November 2, 2016
Highlighted Article: Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Author(s):
Zsuzsanna Suba Pages 254 - 266 ( 13 )
Abstract:
Background: Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures.
Objective: Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration does not work as might be expected; our therapeutic practice requires thorough rethinking.
Method: Published long-term therapeutic results on breast cancer cases were analyzed in correlation with stage at diagnosis, ER-status of tumors and patients’ age. The effectiveness of current therapeutic measures was also compared by estimating the rate of tumor-free survival, breast cancer recurrence and breast cancer-specific mortality.
Results: Diagnosis and treatment of breast cancer at an early stage cannot improve the rate of tumor-free survival. Poor differentiation of tumors, ER-negativity in particular, defines poor prognosis even after applying aggressive therapies. In patients treated with in situ breast cancer, the recurrence-rate of invasive tumor increased directly with ageing irrespective of tumor size or ER-status at diagnosis. Women who underwent lumpectomy without adjuvant radiation or chemotherapy exhibited significantly better overall and breast cancer specific survival rates than those receiving mastectomy, regardless of stage and ER-status of tumors. Antiestrogen treatment exhibited unforeseeable effectiveness even on targeted ERpositive tumors. Recent patents propose the detection of ESR1-gene amplification or restoration of ER-alpha expression for prediction of effective antiestrogen treatment, suggesting a crucial inhibitory role of estrogen-signaling against tumorgrowth.
Conclusion: Estradiol-induced upregulation of estrogen signaling coupled with sparing of the estrogen-rich mammary fatpad are the most effective strategies against breast cancer.
Keywords:
Antiestrogen resistance, breast cancer risk, DNA-stabilization, estradiol therapy, estrogen signaling, lumpectomy, mastectomy, protective adipocytes, radiation therapy.
Affiliation:
National Institute of Oncology, Surgical and Molecular Tumor Pathology Centre, Address: H-1122, Ráth György str. 7-9, Budapest, Hungary.
For More Information Please Visit Our Website Recent Patents on Anti-Cancer Drug Discovery
Monday, October 24, 2016
Most Cited Article: HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
HSP90 Inhibitors: Current
Development and Potential in Cancer Therapy
Author(s):
Katerina Sidera and Evangelia PatsavoudiPages 1-20 (20)
Abstract:
In the last decade, the molecular chaperone HSP90 has emerged as an important target in cancer therapeutics and has subsequently become the focus of several drug discovery and development efforts. The first-in-class HSP90 inhibitor 17-AAG entered into Phase I clinical trial in 1999. Today 13 HSP90 inhibitors representing multiple drug classes, with different modes of action, are undergoing clinical evaluation. The present review will highlight the involvement of HSP90 in regulating and maintaining the transformed phenotype, provide an overview on current HSP90 inhibitors and further update on the most relevant patents which have recently appeared in the literature.
Keywords:
Cancer therapeutics, cell surface, chaperoning, drug discovery,
HSP90, signal transduction.
Affiliation:
Dept. of Biochemistry, Hellenic Pasteur Institute, 127, Vas.
Sofias Av., 11521 Athens, Greece.
For More Information Please Visit Our Website Recent Patents on Anticancer drug Discovery
Tuesday, October 18, 2016
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery*
Article Details
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage
and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving
Surgery*
[ Vol. 11 ,
Issue. 3 ]
Author(s):
Zsuzsanna SubaPages 254-266 (13)
Abstract:
Background: Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures.
Objective: Since the application
of standard therapies, such as surgery, radiation, chemotherapy and
antiestrogen administration does not work as might be expected; our therapeutic
practice requires thorough rethinking.
Method: Published long-term therapeutic
results on breast cancer cases were analyzed in correlation with stage at
diagnosis, ER-status of tumors and patients’ age. The effectiveness of current
therapeutic measures was also compared by estimating the rate of tumor-free
survival, breast cancer recurrence and breast cancer-specific mortality.
Results: Diagnosis and treatment
of breast cancer at an early stage cannot improve the rate of tumor-free
survival. Poor differentiation of tumors, ER-negativity in particular, defines
poor prognosis even after applying aggressive therapies. In patients treated
with in situ breast cancer, the recurrence-rate of invasive tumor increased
directly with ageing irrespective of tumor size or ER-status at diagnosis.
Women who underwent lumpectomy without adjuvant radiation or chemotherapy
exhibited significantly better overall and breast cancer specific survival
rates than those receiving mastectomy, regardless of stage and ER-status of
tumors. Antiestrogen treatment exhibited unforeseeable effectiveness even on
targeted ERpositive tumors. Recent patents propose the detection of ESR1-gene
amplification or restoration of ER-alpha expression for prediction of effective
antiestrogen treatment, suggesting a crucial inhibitory role of
estrogen-signaling against tumorgrowth.
Conclusion: Estradiol-induced
upregulation of estrogen signaling coupled with sparing of the estrogen-rich
mammary fatpad are the most effective strategies against breast cancer.
Keywords:
Antiestrogen resistance, breast
cancer risk, DNA-stabilization, estradiol therapy, estrogen signaling,
lumpectomy, mastectomy, protective adipocytes, radiation therapy.
Affiliation:
National Institute of Oncology,
Surgical and Molecular Tumor Pathology Centre, Address: H-1122, Ráth György
str. 7-9, Budapest, Hungary.
For More Information Please Visit Our Website Recent Patents on Anti-Cancer Drug Discovery
Monday, October 10, 2016
Open Access Plus ::: Recent Patents on Anti-Cancer Drug Discovery
Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Zsuzsanna Suba
Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Sarah Shirley, Alexandre Morizot and Olivier Micheau
Abstract: Literary data suggest apparently ambiguous interaction between menopausal status and obesity-associated breast cancer risk based on the principle of the carcinogenic capacity of estrogen. Before menopause, breast cancer incidence is relatively low and adiposity is erroneously regarded as a protective factor against this tumor conferred by the obesity associated defective estrogen-synthesis. By contrast, in postmenopausal cases, obesity presents a strong risk factor for breast cancer being mistakenly attributed to the presumed excessive estrogen-production of their adipose-tissue mass. Obesity is associated with dysmetabolism and endangers the healthy equilibrium of sexual hormone-production and regular menstrual cycles in women, which are the prerequisites not only for reproductive capacity but also for somatic health…
courtesy by : Bentham Insight
Tuesday, October 4, 2016
Most cited articles from the jorunal ‘Recent Patents on Anti-Cancer Drug Discovery’
Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell Apoptosis
Author(s): Xuan Yuan, Bacui Yu, Yanming Wang, Jiangtao Jiang, Liangliang Liu, Hong Zhao, Wang Qi and Qiusheng Zheng.
Abstract: Isoliquiritigenin (ISL), a licorice chalconoid, is a bioactive agent with chemopreventive potential that has been patented for tumor treatment in China. This study investigated the mechanisms of ISL-induced apoptosis in ovarian carcinoma SKOV-3 cells. Cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. The apoptotic rate was determined via flow cytometry using an annexin V-FITC apoptosis detection kit. The intracellular reactive oxygen species (ROS) levels were assessed using a 2,7-dichlorofluorescein probe assay. Malondialdehyde (MDA) formation was determined via thiobarbituric acid reactive substance test. The expressions of growth arrest and DNA damage-inducible gene (GADD153/CHOP), 78 kDa glucose-regulated protein (GRP 78), α-subunit of eukaryotic initiation factor 2 (eIF2α) phosphorylation, activating transcription factor 6α (ATF6α), and unspliced form of X-box binding protein1 (XBP1U) were analyzed via Western blot. Caspase-3 and caspase-12 activities were assessed using a fluorometric kit.
-See more at http://eurekaselect.com/107356/article
The Need for Calcium Channels in Cell ProliferationAuthor(s): Thierry CapiodAbstract: Both increases in the basal cytosolic calcium concentration ([Ca2+]cyt) and [Ca2+]cyt transients play a major role in cell cycle progression, cell proliferation and division. Calcium influx and release from endoplasmic reticulum are the major routes involved in the variations in [Ca2+]cyt and past studies have clearly shown that calcium influx controls cell growth and proliferation in several cell types. Furthermore, various studies in the past thirty years have demonstrated that calcium channel expression levels, as well as cell specific expression, were determinant in these physiological processes– See more at: http://www.eurekaselect.com/104501/article#sthash.5nVaXVUQ.dpuf | |
Involvement of Endoplasmic Reticulum Stress in Isoliquiritigenin-Induced SKOV-3 Cell ApoptosisAuthor(s): Xuan Yuan, Bacui Yu, Yanming Wang, Jiangtao Jiang, Liangliang Liu, Hong Zhao, Wang Qi and Qiusheng Zheng.Abstract: Isoliquiritigenin (ISL), a licorice chalconoid, is a bioactive agent with chemopreventive potential that has been patented for tumor treatment in China. This study investigated the mechanisms of ISL-induced apoptosis in ovarian carcinoma SKOV-3 cells. Cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. The apoptotic rate was determined via flow cytometry using an annexin V-FITC apoptosis detection kit. The intracellular reactive oxygen species (ROS) levels were assessed using a 2,7-dichlorofluorescein probe assay. Malondialdehyde (MDA) formation was determined via thiobarbituric acid reactive substance test. The expressions of growth arrest and DNA damage-inducible gene (GADD153/CHOP), 78 kDa glucose-regulated protein (GRP 78), α-subunit of eukaryotic initiation factor 2 (eIF2α) phosphorylation, activating transcription factor 6α (ATF6α), and unspliced form of X-box binding protein1 (XBP1U) were analyzed via Western blot. Caspase-3 and caspase-12 activities were assessed using a fluorometric kit.-See more at http://eurekaselect.com/107356/articleThe Need for Calcium Channels in Cell ProliferationAuthor(s): Thierry CapiodAbstract: Both increases in the basal cytosolic calcium concentration ([Ca2+]cyt) and [Ca2+]cyt transients play a major role in cell cycle progression, cell proliferation and division. Calcium influx and release from endoplasmic reticulum are the major routes involved in the variations in [Ca2+]cyt and past studies have clearly shown that calcium influx controls cell growth and proliferation in several cell types. Furthermore, various studies in the past thirty years have demonstrated that calcium channel expression levels, as well as cell specific expression, were determinant in these physiological processes– See more at: http://www.eurekaselect.com/104501/article#sthash.5nVaXVUQ.dpuf
Courtney by: https://benthamsciencepublishers.wordpress.com/2015/11/09/most-cited-articles-from-the-jorunal-recent-patents-on-anti-cancer-drug-discovery-2/
|
New Issue::: Recent Patents on Anti-Cancer Drug Discovery, 11 Issue 1
Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles, and guest edited thematic issues on recent patents in the field of anti-cancer drug discovery e.g. on novel bioactive compounds, analogs & targets. The journal also publishes book reviews of eBooks and books on anti-cancer drug discovery. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery. The journal also covers recent research (where patents have been registered) in fast emerging therapeutic areas/targets & therapeutic agents related to anti-cancer drug discovery.
Articles from the journal in Recent Patents on Anti-Cancer Drug Discovery, 11 Issue 1
- Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
- Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
- Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
- Trends in Biotechnological Drugs for Cancer Treatment
- Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
For details on the articles, please visit this link :: http://bit.ly/1TBgICQ
courtesy by : Bentham Insight
Video presentation on the journal ‘Recent Patents on Anti-Cancer Drug Discovery ‘
Recent Patents on Anti-Cancer Drug Discovery publishes review and research articles, and guest edited thematic issues on recent patents in the field of anti-cancer drug discovery.
Details here: http://bit.ly/1i3VfD1
courtesy by : https://benthamsciencepublishers.wordpress.com/2015/10/06/video-presentation-on-the-journal-recent-patents-on-anti-cancer-drug-discovery/
Last published issue of 2015 of the journal ‘Recent Patents on Anti-Cancer Drug Discovery’ is now available online
Recent Patents on Anti-Cancer Drug Discovery,Volume 10–Number 3
pH Gradient Reversal: An Emerging Hallmark of Cancers,
10(3): 244 – 258
Mohit Sharma, Madhusudan Astekar, Sonal Soi, Bhari S. Manjunatha,Devi C. Shetty and Raghu Radhakrishnan.
10(3): 244 – 258
Mohit Sharma, Madhusudan Astekar, Sonal Soi, Bhari S. Manjunatha,Devi C. Shetty and Raghu Radhakrishnan.
Cabozantinib in Thyroid Cancer
Poupak Fallahi, Silvia M. Ferrari, Flavia Di Bari, Gabriele Materazzi,Salvatore Benvenga, Paolo Miccoli and Alessandro Antonelli.
FOXM1 and its Oncogenic Signaling in Gastric Cancer
Hanying Wang and Chen Huang.
Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Purine Analogues as Kinase Inhibitors: A Review
“Impact of Smoking Cessation Treatment” on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study
Aldo Pezzuto, Luciano Stumbo, Marco Russano, Pierfilippo Crucitti,Simone Scarlata, Marco Caricato and Giuseppe Tonini.
For more information, click here: http://benthamscience.com/journal/index.php?journalID=rpacdd
courtesy by : Bentham Insight
Friday, August 12, 2016
Friday, June 24, 2016
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Author(s):
Sarah Shirley, Alexandre Morizot and Olivier MicheauPages 311-323 (13)
Abstract:
The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
Keywords:
chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L
Affiliation:
INSERM, U866, Dijon, F- 21079 France; Faculty of Medicine and Pharmacy, University of Bourgogne, Dijon, F-21079 France.
Read Full-Text article
Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Author(s):
Zsuzsanna SubaPages 154-167 (14)
Abstract:
Literary data suggest apparently ambiguous interaction between menopausal status and obesity-associated breast cancer risk based on the principle of the carcinogenic capacity of estrogen. Before menopause, breast cancer incidence is relatively low and adiposity is erroneously regarded as a protective factor against this tumor conferred by the obesity associated defective estrogen-synthesis. By contrast, in postmenopausal cases, obesity presents a strong risk factor for breast cancer being mistakenly attributed to the presumed excessive estrogen-production of their adipose-tissue mass. Obesity is associated with dysmetabolism and endangers the healthy equilibrium of sexual hormone-production and regular menstrual cycles in women, which are the prerequisites not only for reproductive capacity but also for somatic health. At the same time, literary data support that anovulatory infertility is a very strong risk for breast cancer in young women either with or without obesity. In the majority of premenopausal women, obesity associated insulin resistance is moderate and may be counteracted by their preserved circulatory estrogen level. Consequently, it is not obesity but rather the still sufficient estrogen-level, which may be protective against breast cancer in young adult females. In obese older women, never using hormone replacement therapy (HRT) the breast cancer risk is high, which is associated with their continuous estrogen loss and increasing insulin-resistance. By contrast, obese postmenopausal women using HRT, have a decreased risk for breast cancer as the protective effect of estrogen-substitution may counteract to their obesity associated systemic alterations. The revealed inverse correlation between circulatory estrogen-level and breast cancer risk in obese women should advance our understanding of breast cancer etiology and promotes primary prevention measures. New patents recommend various methods for the prevention and treatment of obesity-related systemic disorders and the associated breast cancer.
Keywords:
Androgen, breast cancer risk, estrogen, insulin resistance, menopause, metabolic syndrome, obesity, type-2 diabetes, visceral adiposity
Affiliation:
National Institute of Oncology, Surgical and Molecular Tumor Pathology Centre, Address: H-1122 Rath Gyorgy str. 7-9, Budapest, Hungary.
Read Full-Text article
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery
Author(s):
Zsuzsanna SubaPages 1-13 (13)
Abstract:
Background. Results of long-term studies justify that the rate of breast cancer recurrence and tumor-related mortality remains quite unpredictable, regardless of the use of any current therapeutic measures.
Objective. Since the application of standard therapies, such as surgery, radiation, chemotherapy and antiestrogen administration does not work as might be expected; our therapeutic practice requires thorough rethinking.
Method. Published long-term therapeutic results on breast cancer cases were analyzed in correlation with stage at diagnosis, ER-status of tumors and patients’ age. The effectiveness of current therapeutic measures was also compared by estimating the rate of tumor-free survival, breast cancer recurrence and breast cancer-specific mortality.
Results. Diagnosis and treatment of breast cancer at an early stage cannot improve the rate of tumor-free survival. Poor differentiation of tumors, ER-negativity in particular, defines poor prognosis even after applying aggressive therapies. In patients treated with in-situ breast cancer, the recurrence-rate of invasive tumor increased directly with ageing irrespective of tumor size or ER-status at diagnosis. Women who underwent lumpectomy without adjuvant radiation or chemotherapy exhibited significantly better overall and breast cancer specific survival rates than those receiving mastectomy, regardless of stage and ER-status of tumors. Antiestrogen treatment exhibited unforeseeable effectiveness even on targeted ER-positive tumors. Recent patents propose the detection of ESR1-gene amplification or restoration of ER-alpha expression for prediction of effective antiestrogen treatment, suggesting a crucial inhibitory role of estrogen-signaling against tumor-growth.
Conclusion. Estradiol-induced upregulation of estrogen signaling coupled with sparing of the estrogen-rich mammary fatpad are the most effective strategies against breast cancer.
Keywords:
Antiestrogen resistance, breast cancer risk, DNA-stabilization, estradiol therapy, estrogen signaling, lumpectomy, mastectomy, protective adipocytes, radiation therapy
Affiliation:
National Institute of Oncology Surgical and Molecular Tumor Pathology Centre Address: H-1122, Ráth György str. 7-9 Budapest, Hungary
Read Full-Text article
